Literature DB >> 1657755

Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization.

R A McKinnon1, P D Hall, L C Quattrochi, R H Tukey, M E McManus.   

Abstract

To better characterize the precise cellular distribution of CYP1A gene products in man, we have undertaken Northern-blot and in situ hybridization analyses of CYP1A expression in human liver. Using riboprobes transcribed from both CYP1A1 and CYP1A2 complementary DNAs to probe a series of Northern blots of 23 human liver messenger RNA samples, CYP1A1 expression was demonstrated in 11 samples and CYP1A2 expression was evident in 22 samples. The level of expression of both CYP1A enzymes in these livers demonstrated marked variability. The CYP1A1 and CYP1A2 riboprobes were then used for in situ hybridization localization of CYP1A1/1A2 messenger RNA sequences on paraffin-embedded, formalin-fixed human liver sections. These studies demonstrated that both CYP1A1 and CYP1A2 messenger RNAs are distributed nonuniformly across the human liver acinus, with levels highest in hepatocytes surrounding terminal hepatic venules and intercalated veins. Immunohistochemistry with an anti-rabbit CYP1A1 serum demonstrated a corresponding distribution for the translated CYP1A proteins. In situ hybridization analysis was also performed on sections of hepatocellular carcinoma, demonstrating a significant down-regulation in CYP1A expression. Functional studies using the activation of the food-derived heterocyclic amine MeIQ (2-amino-3,4-dimethylimadazo [4,5-f] quinoline) to a mutagen in the Ames test as an indicator of CYP1A expression confirmed this down-regulation. These results demonstrate heterogeneity of hepatic CYP1A expression both between individuals and in different acinar zones. This variation in expression may be of significance in assessing cell specific toxicities of various drugs and carcinogens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657755     DOI: 10.1002/hep.1840140517

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Biotransformation of caffeine by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; S Krahenbuhl; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism.

Authors:  S Gates; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 4.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

5.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

6.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450.

Authors:  H R Ha; J Chen; A U Freiburghaus; F Follath
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Authors:  Dong Gui Hu; Theresa E Hickey; Connie Irvine; Dhilushi Dodampege Wijayakumara; Lu Lu; Wayne D Tilley; Luke A Selth; Peter I Mackenzie
Journal:  Horm Cancer       Date:  2014-02-26       Impact factor: 3.869

8.  Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.

Authors:  R A McKinnon; W M Burgess; P M Hall; S J Roberts-Thomson; F J Gonzalez; M E McManus
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

Review 9.  Current Modalities for the Assessment of Future Remnant Liver Function.

Authors:  Fadi Rassam; Pim B Olthof; Roelof J Bennink; Thomas M van Gulik
Journal:  Visc Med       Date:  2017-11-30

Review 10.  Metabolic activation of toxins: tissue-specific expression and metabolism in target organs.

Authors:  O Pelkonen; H Raunio
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.